Skip to main content

Table 3 Demographic data from the five breast cancer prevention trials

From: Future possibilities in the prevention of breast cancer: Breast cancer prevention trials

     

Compliance (%)

 

Trial

Age (median; years)

Age <50 years (%)

First-degree relative with breast cancer (%)

Two or more relatives with breast cancer (%)

Tamoxifen/raloxifene

Placebo

HRT use on study (%)

RMH [5*]

47

62

96

42

74

86

26

NSABP [3*]

50-59

37

76

33

76

80

<10

Italian [6*]

51

38

12

?

80

75

12

IBIS*

50

51

91

30

74 at 4 years

 

22

MORE [7*]

67

Very few

12†

?

78 at 3 years

75

10‡

  1. *As of 1 December 1999 (accrual ongoing). †Defined as 'family history of breast cancer'. ‡Raloxifene stopped when oestrogen started.